Zai Lab Limited — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Unaudited U.S. GAAP results; monetary amounts are U.S. dollars unless noted. Zai Lab is a commercial-stage biopharmaceutical company focused on oncology, autoimmune disorders, infectious diseases, and neuroscience, with principal markets in Greater China. It reported four commercial products and 13 late-stage development programs.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $62.8 million | $46.7 million | +34% |
| Net product revenue | $62.8 million | $46.1 million | +36% |
| Gross profit and gross margin | $41.5 million; 66.0% | $31.1 million; 66.2% | Margin broadly stable |
| Operating loss | $69.5 million | $79.8 million | Loss narrowed $10.2 million |
| Net loss | $49.1 million | $82.4 million | Loss narrowed $33.3 million |
| Net loss per ADS | $0.51 | $0.86 | Loss per ADS narrowed |
| Cash used in operating activities | $69.3 million | $87.1 million | Use decreased $17.8 million |
Product revenue by product was ZEJULA $42.7 million (+44%), Optune $13.3 million (+4%), QINLOCK $1.3 million (-56%), and NUZYRA $5.5 million (+637%). The filing attributes overall product growth primarily to increased sales volumes.
At March 31, cash and cash equivalents were $879.8 million, short-term investments $50.6 million, and restricted cash $1.0 million. The company reported $931.4 million in combined cash, cash equivalents, restricted cash, and short-term investments. Total assets were $1.17 billion, total liabilities $168.8 million, and shareholders’ equity $1.00 billion. The presented balance sheet does not list borrowings. Current liabilities were $124.6 million. Cash, cash equivalents, and restricted cash decreased $128.4 million during the quarter.
Investing activities used $54.0 million, including purchases of short-term investments; financing activities used $3.9 million, mainly reflecting employee taxes on equity awards. Capital expenditure purchase commitments were $6.0 million, expected within one year. The company said its May 9 cash and investment resources were expected to fund operating expenses and capital requirements for at least 12 months under its current operating plan.
Changes, outlook, and notable items
- Research and development expense declined 10% to $48.5 million, largely because collaboration partners compensated the company for clinical-trial costs. Selling, general, and administrative expense increased 10% to $62.5 million, driven by personnel and professional-service costs.
- Net loss improvement also reflected higher interest income ($10.2 million versus $0.2 million), foreign-currency gains ($8.9 million versus $2.3 million), and a shift in investment fair-value results. These items helped reduce net loss but do not represent product revenue.
- Q1 product revenue included a negative $3.9 million adjustment to compensate distributors for QINLOCK and NUZYRA sales made before NRDL-related price reductions. The updated NRDL took effect March 1, 2023. Management cited COVID-related disruptions to patient access, hospital access, diagnosis, and treatment as a continuing headwind.
- Management expects substantial continuing R&D investment and anticipates higher selling and administrative costs as commercial and development activities expand. The company has incurred losses and negative operating cash flow since inception; it provided no specific revenue or earnings guidance in this filing.
- Potential development, regulatory, and sales-based milestone payments under licensing arrangements could total approximately $5.30 billion, plus royalties, if triggering milestones occur. The company recorded $1.0 million of license-fee and milestone R&D expense in Q1. No material new collaboration agreement or material upfront or milestone payment for existing agreements was reported in the quarter.
- Developments included QINLOCK and NUZYRA NRDL listings, additional Optune supplemental insurance coverage, and regulatory or clinical progress across multiple pipeline programs. In April 2023, the company announced a global license and partnership for the ZL-1310 DLL3 ADC program; this was after quarter-end.
- Material risks include clinical and regulatory uncertainty, commercialization and product-supply risks, COVID-related disruption, and regulatory, political, data-transfer, foreign-exchange, and capital-raising uncertainty related to China. The CSRC’s overseas securities offering filing rules became effective March 31, 2023. Chinese subsidiaries’ $456.0 million of paid-in capital was identified as restricted net assets; RMB conversion and transfers are subject to controls.
- The company reported no material legal proceedings. Management concluded disclosure controls and procedures were effective as of March 31, 2023, with no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether revenue growth, especially ZEJULA and NUZYRA, continues after NRDL price reductions and distributor rebates.
- Whether the stated minimum 12-month liquidity runway remains adequate as pipeline spending and commercial costs evolve; review operating cash burn and investment balances.
- How much future milestone and royalty obligations may be triggered, and the timing and financing implications of those obligations.
- Clinical, regulatory, and commercialization milestones for the 13 late-stage programs, including progress and risks in Greater China and global partner programs.
- Potential effects of China-related regulation, data-transfer restrictions, RMB convertibility, and the concentration of receivables: the two largest customers represented approximately 29% of accounts receivable at quarter-end.